Open AccessLYMPHOCYTIC RNA AS A POSSIBLE ADJUVANT WHEN CREATING ANTIVIRAL VACCINES: REFLECTIONS, ASSUMPTIONS AND REAL POSSIBILITIES OF THEIR IMPLEMENTATION
Author(s) -
A.G. Babaeva,
N.M. Gevorkyan,
N.V. Tishevskaya,
A.E. Zotikov
Publication year - 2021
Publication title -
vestnik rossijskoj akademii estestvennyh nauk
Language(s) - English
Resource type - Journals
eISSN - 1727-7892
pISSN - 1682-1696
DOI - 10.52531/1682-1696-2021-21-1-32-38
Subject(s) - adjuvant , rna , immunity , immunology , peripheral blood , function (biology) , biology , immune system , medicine , microbiology and biotechnology , biochemistry , gene
Previously, we have demonstrated, using several experimental models, the presence of a pronounced morphogenetic activity of total RNA preparations isolated from lymphoid cells of healthy young animals, as well as lymphocytes of human peripheral blood, and the adequacy of this activity to that of the lymphocytes themselves was proved. Based on the revealed properties of such preparations, we propose to use the total RNA obtained from lymphocytes at the earliest stage of the recovery process in vaccinology as a universal adjuvant that will accelerate the induction of the reactivity of the infected person’s lymphocytes and increase the level of their activity, and therefore, enhance the body’s defense function and increase the duration of the immunity produced.